59
+5.36%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ribomic
Its shares trade on Tokyo Stock Exchange under the ticker 4591.T. It has been listed since 25 September 2014. In the fiscal year to 31 March 2026, it reported revenue of ¥3.0m and a net loss of ¥1.15bn. At that date it held total assets of ¥2.98bn and shareholders' equity of ¥2.84bn.
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2014-09-25. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 Sept 2014
- Employees
- 25
- Website
- ribomic.com ↗
Leadership
Pay as last reported
- Dr. Yoshikazu NakamuraPresident, Chief Executive Officer, Representative Director, since 2012
- Mr. Hisato OiwaChief Financial Officer, Executive Officer, Chief Director of Administration, Director, since 2021
- Mr. Shoji YonebayashiExecutive Officer, Director of Accounting and Finance
- Mr. Wataru YonebayashiExecutive Officer, Director of Finance and Accounting
- Mr. Taro NishikidoExecutive Officer, Director of General Affairs and Human Resources, Manager of Internal Audit Office
- Mr. Kenro AndoExecutive Officer, Chief Director of Research and Development, Director, since 2025
- Mr. Tatsuo AdachiExecutive Officer, Director of Exploratory Research
- Mr. Kazumasa AkitaExecutive Officer, Director of Business Development, since 2023
- Mr. Ryoji FutagawaExecutive Officer, Director of Development Research
- Mr. Satoshi IshimaruExecutive Officer, Director of Intellectual Property Science, since 2023
- Mr. Shomi NakajimaExecutive Officer, Director of Legal Affairs
- Mr. Yoshihide NakamuraExecutive Officer, Chief Director of Research and Development, Director of Clinical Development, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ribomic Inc employs 25 full-time employees in Minato-ku, Tokyo.
- Ribomic Inc's self drug discovery division develops aptamer and licenses results to pharma companies.
- Ribomic Inc's co-discovery division shares research expenses with alliance partners in pharma.
Weaknesses
- Ribomic Inc has a small employee count of 25 full-time staff.
- Ribomic Inc's business model relies on co-discovery with alliance partners for research expenses.
- Ribomic Inc's IPO was on 25 September 2014, a relatively recent listing.
Opportunities
- Ribomic Inc's RNA aptamer technology offers potential in therapeutic fields for new drug development.
- Ribomic Inc can expand its self discovery division to develop more aptamer-based drugs.
- Ribomic Inc can form new alliances with pharmaceutical companies for co-discovery business.
Threats
- Ribomic Inc faces competition from other biotechnology firms in RNA aptamer research.
- Ribomic Inc's small size may limit its ability to compete with larger pharmaceutical companies.
- Ribomic Inc's reliance on alliance partners for co-discovery could lead to dependency risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.